Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically
aggressive hematological malignancy with high rates of disease relapse and a poor …

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …

The immune system includes an array of specialized cells that keep us healthy by
responding to pathogenic cues. Investigations into the mechanisms behind immune cell …

Chimeric antigen receptor (CAR) T cell therapy is a form of adoptive cell therapy that has
revolutionized the field of cancer immunotherapy. Owing to the unprecedented efficacy seen …

Chimeric antigen receptor T cell (CAR-T) immunotherapy has revolutionized the treatment of
relapsed and refractory B cell-derived hematological malignancies. Currently, there are six …

A versatile, safe, and effective small-molecule control system is highly desirable for clinical
cell therapy applications. Therefore, we developed a two-component small-molecule control …

Engineering human T cells for the treatment of cancer, viral infections and autoimmunity has
been a long-standing dream of many immunologists and hematologists. Although primary …

Adoptive immunotherapy in the T cell landscape exhibits efficacy in cancer treatment. Over
the past few decades, genetically modified T cells, particularly chimeric antigen receptor T …

Chimeric antigen receptor T cell therapy (CAR-T) is a novel treatment that has produced
unprecedented clinical effects in patients with hematological malignancies. Acute adverse …